EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression

Peter Riederer, Sabrina Strobel, Toshiharu Nagatsu, Hirohisa Watanabe, Xiqun Chen, Peter-Andreas Löschmann, Jeswinder Sian-Hulsmann, Wolfgang H Jost, Thomas Müller, Johannes M Dijkstra, Camelia-Maria Monoranu iD

Journal of Neural Transmission · 2025-06 · 132 (6) · 743-779

DOI: 10.1007/s00702-025-02893-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 11.04.2025. Verfasst von Peter Riederer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, University of Wuerzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Antiparkinson Agents. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 375 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Julius-Maximilians-Universität Würzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment with levodopa, a precursor of dopamine (DA), to compensate for the loss of endogenous DA in Parkinson’s disease (PD), has been a success story for over 50 years. However, in late stages of PD, the progressive degeneration of dopaminergic neurons and the ongoing reduction in endogenous DA concentrations make it increasingly difficult to maintain normal-like DA function. Typically, in late PD, higher doses of levodopa are required, and the fluctuations in striatal DA concentrations—reflecting the timing pattern of levodopa administrations—become more pronounced. These DA fluctuations can include highs that induce involuntary movements (levodopa-induced dyskinesia, LID) or lows that result in insufficient suppression of PD symptoms (“OFF” phases). The enhanced fluctuations primarily arise from the loss of DA buffering capacity, resulting from the degeneration of DA neurons, and an increased reliance on levodopa-derived DA release as a “false neurotransmitter” by serotonergic neurons. In many patients, the LID and OFF-phases can be alleviated by modifying the levodopa therapy to provide a more continuous delivery or by using additional medications, such as monoamine oxidase-B (MAO-B) inhibitors, amantadine, or dopaminergic receptor agonists. Understanding the challenges faced by levodopa therapy also requires considering that the PD striatum is characterized not only by the loss of DA neurons but also by neuroplastic adaptations and PD-induced degenerations of other neural populations. This review provides a broad overview on the use of levodopa in treating PD, with a focus on the underlying science of the challenges encountered in late stages of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseAntiparkinson AgentsHumansDisease ProgressionAnimals

Stichwörter der Autor:innen

LevodopaLevodopa-induced dyskinesia (LID)Long duration response (LDR)Mode of actionOFF-phaseParkinson’s diseaseProgression

Substanzen

LevodopaAntiparkinson Agents

Autor:innen und Institutionen

  • Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, University of Wuerzburg, Würzburg, Germany.
  • Department of Psychiatry, University of South Denmark, Odense, Denmark.
  • Institute of Pathology, Julius-Maximilian-University of Wuerzburg, Würzburg, Germany.
  • Center for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan.
  • Department of Neurology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.
  • Mass. General Institute for Neurodegenerative Disease. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.

ORCID-Profile: Camelia-Maria Monoranu

Förderung

  • Julius-Maximilians-Universität Würzburg

Zitieren

APA

Riederer, P., Strobel, S., Nagatsu, T., Watanabe, H., Chen, X., Löschmann, P. A., Sian-Hulsmann, J., Jost, W. H., Müller, T., Dijkstra, J. M., & Monoranu, C. M. (2025). Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression. Journal of Neural Transmission, 132(6), 743-779. https://doi.org/10.1007/s00702-025-02893-4

Vancouver

Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, Löschmann PA, et al. Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression. Journal of Neural Transmission. 2025;132(6):743-779. doi:10.1007/s00702-025-02893-4

BibTeX
@article{Riederer2025,
  author = {Riederer, Peter and Strobel, Sabrina and Nagatsu, Toshiharu and Watanabe, Hirohisa and Chen, Xiqun and Löschmann, Peter-Andreas and Sian-Hulsmann, Jeswinder and Jost, Wolfgang H and Müller, Thomas and Dijkstra, Johannes M and Monoranu, Camelia-Maria},
  title = {Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression},
  journal = {Journal of Neural Transmission},
  year = {2025},
  volume = {132},
  number = {6},
  pages = {743--779},
  doi = {10.1007/s00702-025-02893-4}
}
Kostenlos starten →